

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
**WO 2004/026189 A2**

(51) International Patent Classification<sup>7</sup>: A61F 2/44

RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2003/029278

(22) International Filing Date:

16 September 2003 (16.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10/245,955 18 September 2002 (18.09.2002) US

(71) Applicant (for all designated States except US): SDGI  
HOLDINGS, INC. [US/US]; 300 Delaware Avenue Suite  
508, Wilmington, DE 19801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): TRIEU, Hai, H.  
[US/US]; 1323 Graystone Lane, Cordova, TN 38018 (US).  
SHERMAN, Michael, C. [US/US]; 5854 Haymaker  
Road, Memphis, TN 38120 (US).

(74) Agents: BINDSEIL, James, J. et al.; LC340, 710  
Medtronic Parkway NE, Minneapolis, MN 55432 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,  
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO  
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,  
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,  
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: COLLAGEN-BASED MATERIALS AND METHODS FOR AUGMENTING INTERVERTEBRAL DISCS

(57) Abstract: A method of augmenting an intervertebral disc by injecting particles of collagen-based material into the disc. The particles may be dehydrated before implantation, and rehydrated after implantation, or they may be implanted in a "wet" state - such as a slurry or gel. Radiocontrast materials may be included to enhance imaging of the injected material. Other additives may include analgesics, antibiotics, proteoglycans, growth factors, and/or other cells effective to promote healing and/or proper disc function.

WO 2004/026189 A2

## COLLAGEN-BASED MATERIALS AND METHODS FOR AUGMENTING INTERVERTEBRAL DISCS

5

### FIELD OF THE INVENTION

The present invention relates generally to materials and methods for augmenting intervertebral discs, and more particularly to materials and methods for augmenting intervertebral discs with collagen-based materials.

10

### BACKGROUND OF THE INVENTION

A healthy intervertebral disc facilitates motion between pairs of vertebrae while absorbing and distributing shocks. The disc is composed of two parts: a soft central core (the nucleus pulposus) that bears the majority of the load, and a tough outer ring (the annulus fibrosis) that holds and stabilizes the core material.

15

As the natural aging process progresses, the disc may dehydrate and degenerate, adversely affecting its ability to adequately cushion and support the vertebral bodies. This natural desiccation, which in its more advanced state is often referred to as "black disc" because of the disc's dehydrated appearance on Magnetic Resonance Imaging [MRI], can cause discomfort to the patient as the vertebrae to come closer together – compressing the spinal nerves and causing pain.

20

Techniques for addressing degenerative disc disease have heretofore relied primarily on disc replacement methods. In cases in which a dehydrated and/or degenerating disc was augmented before disc replacement was required, the augmentation materials have primarily been synthetic devices that expand, are inflated, or deploy expanding elements when implanted into the disc.

25

A need therefore exists for materials and methods effective for augmenting intervertebral discs with natural materials. The present invention addresses that need.

30

### SUMMARY OF THE INVENTION

Briefly describing one aspect of the present invention, there is provided a method of augmenting an intervertebral disc by injecting particles of collagen-based material into the disc. The particles may be implanted in a dehydrated form, and rehydrated after

implantation, or they may be implanted in a hydrated form, such as a slurry or gel. Cross-linking agents such as glutaraldehyde may be included in the injected material to promote collagen crosslinking. In addition, radio-contrast materials may be included to enhance imaging of the injected material. Similarly, performance-enhancing additives such as analgesics and/or antibiotics may be included to provide additional therapeutic benefits.

Objects and advantages of the claimed invention will be apparent from the following description.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1D show a procedure for injecting a collagen-based material into an intervertebral disc, according to one preferred embodiment of the present invention.

FIGS. 2A-2F show a procedure for injecting a collagen-based material into an intervertebral disc, according to another preferred embodiment of the present invention.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to certain preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the preferred embodiments being contemplated as would normally occur to one skilled in the art to which the invention relates.

As indicated above, one aspect of the present invention relates to materials and methods for using collagen-based material to augment an intervertebral disc. In the most preferred embodiments the collagen-based material is injected into a disc nucleus that is contained in a substantially sound annulus. In other embodiments the collagen-based material is injected into a disc nucleus that is contained in a damaged or defective annulus.

The collagen-based material is preferably derived from natural, collagen-rich tissue, such as intervertebral disc, fascia, ligament, tendon, demineralized bone matrix, etc. The material may be autogenic, allogenic, or xenogenic, or it may be of human-

recombinant origin. In alternative embodiments the collagen-based material may be a synthetic, collagen-based material. Examples of preferred collagen-rich tissues include disc annulus, fascia lata, planar fascia, anterior or posterior cruciate ligaments, patella tendon, hamstring tendons, quadriceps tendons, Achilles tendons, skins, and other connective tissues.

The collagen-based material may be provided in any form appropriate for introduction into a disc space. For example, the material may be a solid, porous, woven, or non-woven material. The material may be provided as particles or small pieces, or as a fibrous material.

In some embodiments the material is provided in a dehydrated state, and is "rehydrated" after implantation in the disc. In other embodiments the material is implanted "wet." When the material is "wet," it may be that way because it has never been dehydrated, or it may have been dehydrated and reconstituted. When reconstituted, the material may be reconstituted with saline or another aqueous medium, or it may be reconstituted with a non-aqueous medium such as ethylene glycol or another alcohol. Moreover, when provided in a "wet" state, the material may be provided as a gel, solution, suspension, dispersion, emulsion, paste, etc.

In the most preferred embodiments the material is a particulate and/or fibrous material suitable for injection through a hypodermic needle into a disc.

In the most preferred embodiments the collagen material is provided as particles ranging between .05mm and 5mm in size. When materials such as fascia lata or disc annulus particles are used the particles preferably range in size from .1mm to 5mm. When materials such as demineralized bone matrix are used the particles preferably range in size from .05mm to 3mm. When small plugs of material are used the plugs preferably range in size from .5mm to 5mm. In some embodiments larger sized pieces, such as pieces up to 20mm in size, may be used.

The materials may be processed or fabricated using more than one type of tissue. For example, mixtures of fascia lata and demineralized bone matrix may be preferred in appropriate cases, as may mixtures of DBM and annulus fibrosis material.

Cross-linking agents may be added to the formulation to promote cross-linking of the collagen material. For example, glutaraldehyde or other protein cross-linking agents may be included in the formulation. The cross-linking agents may promote covalent or non-covalent crosslinks between collagen molecules. Similarly, agents to inhibit protein denaturization may also be included. Crosslinking agents that would be appropriate for use in the claimed invention are known to persons skilled in the art, and may be selected without undue experimentation.

When the material is to be used as a slurry or gel, additives to promote slurry or gel formation may also be included. These additives may promote protein folding, water binding, protein-protein interactions, and water immobilization.

In addition, a radiocontrast media, such as barium sulfate, or a radiocontrast dye, such as HYPaque®, may be included to aid the surgeon in tracking the movement and/or location of the injected material. Radiocontrast materials appropriate for use in discography are known to persons skilled in the art, and may be selected for use in the present invention without undue experimentation.

Finally, other additives to provide benefits to the injected collagen-based material may also be included. Such additives include anesthetics, to reduce pain caused by the procedure, and antibiotics, to minimize the potential for bacterial infection.

Proteoglycans may also be included to attract and/or bind water to keep the nucleus hydrated. Similarly, growth factors and/or other cells (e.g., intervertebral disc cells, stem cells, etc.) to promote healing, repair, regeneration and/or restoration of the disc, and/or to facilitate proper disc function, may also be included. Additives appropriate for use in the claimed invention are known to persons skilled in the art, and may be selected without undue experimentation.

In some embodiments the collagen material is dehydrated before injection into the disc space, where it is rehydrated by absorbing fluid from the disc space. In other embodiments the collagen material is provided as a gel, slurry, or other hydrated formulation before implantation.

The collagen-based material is “surgically added” to the disc space. That is, the material is added by the intervention of medical personnel, as distinguished from being “added” by the body’s natural growth or regeneration processes. The surgical procedure

preferably includes injection through a hypodermic needle, although other surgical methods of introducing the collagen-based material into the disc may be used. For example, the material may be introduced into a disc by extrusion through a dilated annular opening, infusion through a catheter, insertion through an opening created by trauma or surgical incision, or by other means of invasive or minimally invasive deposition of the materials into the disc space.

Referring now to the drawings, FIGS. 1A-1D show one method of injecting a collagen-based material into a disc. In FIG. 1A, dehydrated particulate fascia lata or annulus fibrosis material 11 is provided in a syringe 12 (in a sterile package). The material is rehydrated and/or dispersed in a suspension medium as shown in FIG. 1B, to provide a wet dispersion 13 of collagen-based material. A hypodermic needle 14 is attached to syringe 12, and the syringe is inserted into a nucleus pulposus 15 contained within a disc annulus 16 (FIG. 1C). The needle/syringe may be moved around within the disc space, sweeping from side to side and back and forth, to ensure uniform distribution of the collagen-based material 13 within the disc space, as shown in FIG. 1D. It is preferred, however, that the tip of the needle be maintained near the center of the disc to ensure deposition of the material within the nuclear disc space, and to minimize potential leakage.

Alternatively, small collagen plugs 21 may be inserted into the disc space as shown in FIGS. 2A-2F. The collagen plugs 21 may be compressed before or by insertion into a small diameter tube 22, and are provided in a delivery cannula 23 (FIGS. 2A-2C). The delivery cannula 23 is attached to a dilator 24.

The compressed plugs are inserted into a disc nucleus 25 having a substantially intact annulus 26 by penetrating the annulus with a guide needle 27 (FIG. 2D). Dilator 24, preferably with delivery cannula 23 already attached, is inserted through the annulus over guide needle 27 (FIG. 2E). The collagen plugs 21 are then ready for injection (or extrusion) into the disc space.

The collagen plugs are deposited into the disc space. As with the wet particulate/fibrous material, the cannula may be moved up and back, and/or side to side, to ensure even distribution of the plugs (FIG. 2F) a plunger 28 may be used to push the plugs from the cannula.



The plugs expand upon exiting the dilator, and may further expand as they rehydrate in the disc space.

As to the benefits of the inventive materials and methods, augmentation of the intervertebral disc may restore or improve the natural condition and/or performance of the disc. In addition, augmentation may retard or reverse the progressive degeneration of a dehydrated disc.

Reference will now be made to specific examples using the processes described above. It is to be understood that the examples are provided to more completely describe preferred embodiments, and that no limitation to the scope of the invention is intended thereby.

#### EXAMPLE 1A

##### Hydrated Particulate Fascia Lata

A suspension of particulate or fibrous (autologous or allogenic) fascia lata is prepared in a biocompatible medium such as saline or ethylene glycol. The particle size ranges from 0.1 mm to 5 mm, with most particles being between 0.25 and 2 mm.

The suspension is injected directly into the nuclear disc space through an intact annulus using a hypodermic needle, and is contained within the disc space following injection. The medium subsequently diffuses out of the disc space and leaves the fascia lata material behind.

Inspection of the disc reveals that an appropriate level of augmentation may be obtained with a single injection of material. Alternatively, several smaller doses/injections may be used to achieve comparable results.

#### EXAMPLE 1B

##### Hydrated Particulate Fascia Lata With Crosslinking Agent

A suspension of particulate or fibrous (autologous or allogenic) fascia lata is prepared in a biocompatible medium such as saline or ethylene glycol. The particle size ranges from 0.1 mm to 5 mm, with most particles being between 0.25 mm and 2 mm. A glutaraldehyde crosslinking agent is added to promote collagen crosslinking.

The suspension is injected directly into the nuclear disc space through an intact annulus using a hypodermic needle, and is contained within the disc space following injection. The medium subsequently diffuses out of the disc space and leaves the fascia lata material behind.

5            Inspection of the disc reveals that an appropriate level of augmentation may be obtained through either a single injection of material, or by multiple injections.

#### EXAMPLE 1C

##### Dehydrated Particulate Fascia Lata

10

Dehydrated fascia lata material is provided in particulate form. Particle sizes range between 0.05 mm and 3 mm, with most particles being between 0.10 mm and 1 mm. The dehydrated material is loaded in a specially designed syringe for delivery of solid materials.

15            The material is extruded into the nuclear disc space of the treated disc through a small dilated annular opening. The material remains inside the disc space after the needle is removed. It subsequently absorbs moisture or body fluids and swells up in vivo.

Inspection of the disc reveals that an appropriate level of augmentation may be obtained through either a single injection of material, or by multiple injections.

20

#### EXAMPLE 2A

##### Hydrated Particulate Disc Annulus Material

25            A suspension of particulate or fibrous allogenic annulus fibrosis is prepared in a biocompatible medium such as saline or ethylene glycol. The particle size ranges from 0.1 mm to 5 mm, with most particles being between 0.25 and 2 mm.

30            The suspension is injected directly into the nuclear disc space through an intact annulus using a hypodermic needle. The suspension is contained within the disc space following injection. The medium subsequently diffuses out of the disc space and leaves the annulus fibrosis material behind.



Inspection of the disc reveals that an appropriate level of augmentation may be obtained through either a single injection of material, or by multiple injections.

#### EXAMPLE 2B

##### 5                    Hydrated Particulate Disc Annulus Material With Crosslinking Agent

10                   A suspension of particulate or fibrous allogenic annulus fibrosis is prepared in a biocompatible medium such as saline or ethylene glycol. The particle size ranges from 0.1 mm to 5 mm, with most particles being between 0.25 and 2 mm. A glutaraldehyde crosslinking agent is added to promote collagen crosslinking.

The suspension is injected directly into the nuclear disc space through an intact annulus using a hypodermic needle. The suspension is contained within the disc space following injection. The medium subsequently diffuses out of the disc space and leaves the annulus fibrosis material behind.

15                   Inspection of the disc reveals that an appropriate level of augmentation may be obtained through either a single injection of material, or by multiple injections.

#### EXAMPLES 3A-3C

##### 20                   Dehydrated Annulus Fibrosis

25                   Dehydrated annulus fibrosis is provided in granule, particulate and powder form, for example 3A-3C respectively. Particle sizes range between 0.05 mm and 3 mm, with most particles being between 0.10 mm and 1 mm. The dehydrated material is loaded in a specially designed syringe for delivery of solid materials.

The material is extruded into the nuclear disc space of the treated disc through a small dilated annular opening. The material remains inside the disc space after the needle is removed. It subsequently absorbs moisture or body fluids and swells up in vivo.

30                   Inspection of the disc reveals that an appropriate level of augmentation may be obtained through either a single injection of material, or by multiple injections.

EXAMPLES 4A-4BDemineralized Bone Matrix (DBM) Gel

5           Demineralized bone matrix (DBM) gel is provided with and without  
glutaraldehyde as a cross-linker additive (examples 4A and 4B, respectively). In both  
cases the material is warmed up to an appropriate temperature for melting or thinning out  
the gel, and is injected directly into the nuclear disc space through an intact annulus using  
a hypodermic needle. The DBM gel becomes solidified in the disc space after injection.

10           Inspection of the disc reveals that an appropriate level of augmentation may be  
obtained through either a single injection of material, or by multiple injections.

EXAMPLES 4CDehydrated Demineralized Bone Matrix (DBM)

15           Dehydrated DBM is provided in granule, particulate and powder form. Particle  
sizes range between 0.05 mm and 3 mm, with most particles being between 0.10 mm and  
1 mm. The dehydrated material is loaded in a specially designed syringe for delivery of  
solid materials.

20           The material is extruded into the nuclear disc space of the treated disc through a  
small dilated annular opening. The material remains inside the disc space after the needle  
is removed. It subsequently absorbs moisture or body fluids and swells up in vivo.

          Inspection of the disc reveals that an appropriate level of augmentation may be  
obtained through either a single injection of material, or by multiple injections.

EXAMPLE 5A-5DMixtures of annulus fibrosis and demineralized bone matrix

30           Mixtures of particulate and fibrous allogenic annulus fibrosis and demineralized  
bone matrix (DBM) gel, with and without additives and/or cross-linkers, are provided.  
The materials are warmed up to an appropriate temperature for melting or thinning out the

gel mixture, and are injected directly into the nuclear disc space through an intact annulus using a hypodermic needle. The gel mixture becomes solidified in the disc space after injection.

Inspection of the disc reveals that an appropriate level of augmentation may be obtained through either a single injection of material, or by multiple injections.

#### EXAMPLE 6

Elongated cylindrical plugs (0.5 mm to 5 mm in diameter, preferably 1 mm to 2 mm) of solid, porous, or fibrous collagen are provided in a dehydrated state. The plugs are compressed in the radial direction and are inserted into delivery cannula for delivery into disc space.

A guide wire or needle is used to penetrate the disc space through an intact annulus. A dilator is subsequently inserted into the disc space over the guide wire/needle, and the guide wire/needle is removed. The delivery cannula containing a collagen plug is attached to the dilator prior to extrusion of the plug into the disc space. As the plugs absorb moisture after entering the disc space, they become more compliant, flexible and expanded.

The level of disc augmentation achieved depends on the number of plugs inserted, and/or on the total plug volume deposited in the disc space.

#### EXAMPLE 7

Cylindrical plugs or rolls (2 mm – 20 mm in diameter, preferably 10 – 15 mm) of solid, porous, or fibrous collagen are provided in a dehydrated state. The dehydrated plugs are typically more rigid than those in hydrated state, and thus, can be easily inserted into the disc space through an annular opening created by trauma or surgical incision.

Nucleotomy is necessary before the plug can be inserted. As the plugs absorb moisture after entering the disc space, they become more compliant, flexible and expanded.

The level of disc augmentation/replacement achieved depends on the size and number of plugs inserted into the disc space.

#### EXAMPLE 8

5

Particulate fascia used for cosmetic procedure (FASCIAN®) was modified to include a radiocontrast media. A small quantity of barium sulfate powder was blended with 80 mg of >0.5 mm Gastrocemius Fascia for visualization under fluoroscopic imaging. About 1-1.5 cc of water was added to the blend in the syringe for hydration.

10

After hydration for 5-10 minutes, the material (Fascian/Barium Sulfate/Water or F.B.W.) was injected into the nuclear disc space of a harvested porcine intervertebral disc. X-ray images of the disc were obtained before and after injection.

15

A small increase in disc height was noticed after injection. Also, manual compression indicated that the disc was stiffer after injection. The injected disc was also tested under compression up to 5000N. There was no gross leakage observed during the compression test. Only a slight oozing of a small amount of injected material was observed at the injection site, but it stopped quickly.

20

The disc was cut in the horizontal plane to confirm the location of the injected material. F.B.W. was found contained within the disc annulus and mixed in with nucleus pulposus.

#### EXAMPLE 9

25

Particulate fascia used for cosmetic procedures (FASCIAN®) was modified before experimentation to include a radiocontrast material. A small quantity of radio-contrast dye or barium sulfate powder was blended with about 200 mg of 0.25 – 1.0 mm Gastrocemius Fascia for visualization under fluoroscopic imaging. About 1.5-3 cc of saline was added to the blend in the syringe for hydration.

30

After hydration for about 30 minutes, the material (Fascian/Dye or Barium Sulfate/Water) was injected into the nuclear disc space of cadaveric intervertebral discs (L2-3 and L3-4). X-ray images of the discs were obtained before and after injection. A

small increase in disc height was noticed radiographically after injection. There was no gross leakage observed at the injection site. In the case of L3-4 injection, the needle tip was maintained approximately at the center of the disc, which resulted in material deposition mainly within the nucleus pulposus.

5

#### EXAMPLE 10

Particulate fascia (FASCIAN®) having particle sizes of 0.25mm and 0.5mm was purchased from Fascia BioSystems. Collagen solutions were prepared, with each solution consisting of approximately 80 mg of particulate fascia, 0.75 ml of saline, and 0.25 ml HYPAQUE® radiocontrast solution.

10

Thoracic and lumbar discs in two pigs were subjected to stabbing injury. The injured discs were then injected with 1-2 ml of collagen solution at 4 weeks after injury. The injections were performed using a 3 ml syringe, a 20 gauge hypodermic needle and a graft placement device. Confirming X-ray was taken using C-arm fluoroscopy.

15

The injured discs appeared to have somewhat reduced heights at four weeks after injury. Of approximately 12 injected discs, there was only one leakage observed. The amount of leakage was visually estimated to be less than 20% of the total volume injected. The low incidence of leakage indicates that the annulus is capable of self-sealing when a small gauge needle is used for injection.

20

The disc height increased upon collagen injection depending on the injected volume. In particular, an approximately 46% increase in disc height was achieved with 2 ml injection. In some cases the disc height gain was reduced after injection as radio-contrast dye and water molecules diffused out of the disc under intra-discal pressure.

25

While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiment has been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected.

30

## CLAIMS

What is claimed is:

1. A method of augmenting an intervertebral disc, said method comprising  
5 surgically adding to an intervertebral disc a composition comprising particulate collagen-based material.
2. The method of claim 1 wherein said surgically adding step comprises injecting particulate collagen-based material into an intervertebral disc.
3. The method of claim 1 wherein said collagen-based material comprises  
10 particles ranging from 0.05mm to 5mm in size.
4. The method of claim 1 wherein said collagen-based material comprises particles ranging from 0.05mm to 3mm in size.
5. The method of claim 1 wherein said collagen-based material comprises particles ranging from 0.05mm to 1mm in size.
- 15 6. The method of claim 1 wherein said collagen-based material comprises particles ranging from 0.25mm to 1mm in size.
7. The method of claim 1 wherein said collagen-based material is injected in a dehydrated state.
8. The method of claim 1 wherein said collagen-based material is injected in a  
20 non-dehydrated state.
9. The method of claim 8 wherein said collagen-based material is injected as a gel.
10. The method of claim 8 wherein said collagen-based material is injected as a solution or suspension.
- 25 11. The method of claim 1 wherein said collagen-based material is provided as a formulation that additionally includes a cross-linking agent to promote crosslinking of collagen molecules.
12. The method of claim 1 wherein said collagen-based material is provided as a formulation that additionally includes a radiocontrast media.
- 30 13. The method of claim 1 wherein said collagen-based material is provided as a formulation that additionally includes an analgesic.



14. The method of claim 1 wherein said collagen-based material is provided as a formulation that additionally includes an antibiotic.

15. The method of claim 1 wherein said collagen-based material is provided as a formulation that additionally includes proteoglycans.

5 16. The method of claim 1 wherein said collagen-based material is provided as a formulation that additionally includes growth factors.

10 17. The method of claim 1 wherein said collagen-based material is provided as a formulation that additionally includes one or more other types of cells effective to promote healing, repair, regeneration and/or restoration of the disc, and/or to facilitate proper disc function.

18. An intervertebral disc augmented with particulate collagen-based material.

19. The augmented disc of claim 18 wherein said collagen-based material comprises collagen-based material that has been injected into the disc.

15 20. The augmented disc of claim 18 wherein said collagen-based material comprises particles ranging from 0.05mm to 5mm in size.

21. The augmented disc of claim 18 wherein said collagen-based material comprises particles ranging from 0.05mm to 3mm in size.

22. The augmented disc of claim 18 wherein said collagen-based material comprises particles ranging from 0.05mm to 1mm in size.

20 23. The augmented disc of claim 18 wherein said collagen-based material comprises particles ranging from 0.25mm to 1mm in size.

24. The augmented disc of claim 18 wherein said collagen-based material comprises collagen-based materials that have been reconstituted in the disc from dehydrated collagen-based materials.

25 25. The augmented disc of claim 18 wherein said collagen-based material comprises collagen-based materials that were injected into the disc in a non-dehydrated state.

26. The augmented disc of claim 18 wherein said collagen-based material comprises collagen-based materials that were injected into the disc as a gel.

27. The augmented disc of claim 18 wherein said collagen-based material comprises collagen-based materials that were injected into the disc as a solution or suspension.

5 28. The augmented disc of claim 18 wherein said collagen-based material additionally includes a cross-linking agent to promote crosslinking of collagen molecules.

29. The augmented disc of claim 18 wherein said collagen-based material additionally includes a radiocontrast media.



30. The augmented disc of claim 18 wherein said collagen-based material additionally includes an analgesic.


10 31. The augmented disc of claim 18 wherein said collagen-based material additionally includes an antibiotic.

32. The augmented disc of claim 18 wherein said collagen-based material additionally includes proteoglycans.


15 33. The augmented disc of claim 18 wherein said collagen-based material additionally includes growth factors.


34. The augmented disc of claim 18 wherein said collagen-based material additionally includes one or more other types of cells effective to promote healing, repair, regeneration and/or restoration of the disc, and/or to facilitate proper disc function.

**Fig. 1A****Fig. 1B**




**Fig. 1C**


**Fig. 1D**



**Fig. 2A**





**Fig. 2B**




**Fig. 2C**



**Fig. 2D**



**Fig. 2E**

**Fig. 2F**